Supplementary Fig. 3 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Nur P. Damayanti(University of Indianapolis), Роберто Пили(Jacobs Institute), W. Marston Linehan, Sheng‐Yu Ku(Roswell Park Comprehensive Cancer Center), Heba W.Z Khella, Sreenivasulu Chintala(UC San Diego Health System), George M. Yousef(University Health Network), Eric Kauffman(Roswell Park Comprehensive Cancer Center), Justin A. Budka(Gilead Sciences (United Kingdom)), Khunsha Ahmed(Indiana University Health), Anthony C. Wood(Moffitt Cancer Center), May Elbanna(Indiana University Health), Remi Adelaiye‐Ogala(Roswell Park Comprehensive Cancer Center), Venkata Nithinsai Chintala(Indiana University Health), Mary W. Ferris(Indiana University Bloomington), Chinghai Kao(University of Virginia), Ashley Orillion(Roswell Park Comprehensive Cancer Center), Peter C. Hollenhorst(Indiana University Bloomington)
Cited by 0
Related Papers
Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines
|International Journal of Cancer|1998|291
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
|Journal of Clinical Investigation|2020|194
miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215
|British Journal of Cancer|2011|163
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells
|Genes & Development|2011|161